Table 2 Triple-negative breast cancers cases: distribution according to miR-30a (5p and 3p) expression, demographics and clinical pathological features

Median follow-up (months)

63.2

61.0

65.4

0.87^c

51.3

67.7

0.06^c

Median age at diagnosis (yrs)

51

49

52

0.50^c

52

50

0.13^c

No. (%)

No. (%)

No. (%)

No. (%)

No. (%)

Tumor size^b

 T1

28 (52.8)

12 (42.9)

16 (64.0)

0.09^d

11 (39.3)

17 (68.0)

0.06^d

 T2

22 (41.5)

13 (46.4)

9 (36.0)

14 (50.0)

8 (32.0)

 T3–T4

3 (5.7)

3 (10.7)

0 (0.0)

3 (10.7)

0 (0.0)

Lymph nodes^b

 N0

28 (47.5)

10 (35.7)

18 (75.0)

0.01^d

9 (32.1)

19 (79.2)

<0.001^d

 N+

24 (40.7)

18 (64.3)

6 (25.0)

19 (67.9)

5 (20.8)

Metastasis

 M0

54 (91.5)

28 (96.6)

26 (86.7)

0.35^d

27 (93.1)

27 (90.0)

1.00^d

 M+

5 (8.5)

1 (3.5)

4 (13.3)

2 (6.9)

4 (10.0)

TNM stage

 I

19 (32.2)

8 (27.6)

11 (36.7)

0.80^d

7 (24.1)

12 (40.0)

0.43^d

 II

25 (42.4)

13 (44.8)

12 (40.0)

13 (44.8)

12 (40.0)

 III–IV

15 (25.4)

8 (27.6)

7 (23.3)

9 (31.0)

6 (20.0)

Tumor grade^b

 G1–G2

3 (5.1)

1 (3.6)

2 (6.7)

1.00^d

0 (0.0)

3 (10.4)

0.24^d

 G3

55 (93.2)

27 (96.4)

28 (93.3)

29 (100.0)

26 (89.7)

Radiation treatment^b

 No

23 (45.1)

10 (38.5)

13 (52.0)

0.40^d

11 (45.8)

12 (55.6)

1.00^d

 Yes

28 (54.9)

16 (61.5)

12 (48.0)

13 (54.2)

15 (44.4)

Pharmacological treatment^b

 No

9 (16.1)

3 (11.1)

6 (20.7)

0.47^d

4 (14.8)

5 (17.2)

1.00^d

 Yes

47 (83.9)

24 (88.9)

23 (79.3)

23 (85.2)

24 (82.8)

Drugs^b

 Anthracycline

21 (47.7)

14 (60.9)

7 (33.3)

0.23^d

11 (52.4)

10 (43.5)

0.73^d

 Anthracycline/Taxanes

11 (25.0)

4 (17.4)

7 (33.3)

4 (19.0)

7 (30.4)

 CMF

12 (27.3)

5 (21.7)

7 (33.3)

6 (28.6)

6 (26.1)